The Medicines (MDCO) Rating Increased to Hold at ValuEngine

The Medicines (NASDAQ:MDCO) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday.

Several other equities analysts have also weighed in on MDCO. Zacks Investment Research upgraded shares of The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Tuesday, August 8th. Cowen reiterated a “buy” rating and issued a $54.00 target price (down from $61.00) on shares of The Medicines in a report on Thursday, August 10th. Jefferies Group reiterated a “buy” rating and issued a $54.00 target price (down from $62.00) on shares of The Medicines in a report on Thursday, August 10th. TheStreet lowered shares of The Medicines from a “c-” rating to a “d” rating in a report on Wednesday, August 9th. Finally, Citigroup cut their target price on shares of The Medicines from $45.00 to $44.00 and set a “neutral” rating on the stock in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The Medicines currently has an average rating of “Buy” and a consensus price target of $53.67.

The Medicines (NASDAQ:MDCO) opened at $28.50 on Friday. The Medicines has a twelve month low of $27.77 and a twelve month high of $55.95. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42.

The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $26.06 million. During the same period in the prior year, the business posted ($0.64) earnings per share. The Medicines’s revenue was down 55.1% compared to the same quarter last year. analysts expect that The Medicines will post -8.86 EPS for the current year.

In related news, Director Alexander J. Denner acquired 170,000 shares of the stock in a transaction dated Wednesday, November 29th. The stock was bought at an average price of $30.03 per share, with a total value of $5,105,100.00. Following the completion of the transaction, the director now directly owns 6,663 shares of the company’s stock, valued at $200,089.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.22% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. First Mercantile Trust Co. grew its position in The Medicines by 2.5% in the second quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock valued at $181,000 after purchasing an additional 114 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in The Medicines by 0.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 39,599 shares of the company’s stock valued at $1,505,000 after purchasing an additional 219 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in The Medicines by 4.2% in the second quarter. Ameritas Investment Partners Inc. now owns 6,058 shares of the company’s stock valued at $230,000 after purchasing an additional 243 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in The Medicines by 10.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $105,000 after purchasing an additional 264 shares in the last quarter. Finally, Arizona State Retirement System grew its position in The Medicines by 1.1% in the second quarter. Arizona State Retirement System now owns 37,596 shares of the company’s stock valued at $1,429,000 after purchasing an additional 400 shares in the last quarter.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/03/the-medicines-mdco-rating-increased-to-hold-at-valuengine.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply